ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock

Inclusion Criteria: * Cardiogenic shock of any cause and indication for VA-ECMO * Age between 18 and 80 * Signed informed consent Exclusion Criteria: * Current participation in another interventional trial * Pregnancy * Current immunosuppressive or immunomodulatory therapy * Contraindications to VA-ECMO implantation. * Patients with pre - existing sepsis (raised CPR, positive PCT, leukozytosis, fever, positive blood cultures). * Shock duration\> 12 h before evaluation. * Severe PVD (peripheral vessel disease) making ECMO-implantation impossible. * Aortic valve insufficiency / stenosis at least II °. * Age \> 80 years. * CNS disease with fixed, dilated pupils (not drug-induced). * Severe concomitant disease with limited life expectancy \<6 months. * CPR\> 60min. * Shock due to other reasons * HIT positive (Heparin induced thrombocytopenia) * Very low platelet counts (\< 20,000/µl) * Body weight less than 45 kg